Tools
Stock profile

Medline Inc. (MDLN)

MDLN · Latest close $39.16 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$39.16
As of Nov 18, 2026
Tracked funds holding
6 of 149
2026 Q2 13F filings
Opened / added
0 / 2
vs previous quarter
Trimmed / exited
3
vs previous quarter

Medline Inc. (MDLN) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding and 3 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $996.4M sold). Latest close $39.16 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 8, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-996.4M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Egerton Capital · Lone Pine Capital · Durable Capital Partners — 6 tracked funds hold MDLN. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 6 sales ($996.4M). Insider trading

Often held alongside

Oruka Therapeutics, Inc. (ORKA) · Interactive Brokers Group, Inc. (IBKR) · Natera, Inc. (NTRA) · CARVANA CO. (CVNA) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Egerton Capital6.28%16,470,884ADDED (+277.3%) Q3 filed Oct 20
Lone Pine Capital5.06%20,968,367ADDED (+77.9%) Q3 filed Nov 16
Durable Capital Partners1.01%2,627,321TRIMMED (-63.8%) Q3 filed Nov 16
Viking Global Investors0.54%4,841,080TRIMMED (-57.7%) Q3 filed Nov 16
RTW Investments0.02%70,000HELD Q3 filed Nov 16
Perceptive Advisors0.02%28,000HELD Q3 filed Nov 16
Maverick Capital——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -9.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

49.9930.912025-12-172026-11-18

Closing prices (unadjusted for dividends), last 2 years — 232 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding402 of 8,857 filers
Long-only filers among them402
Change vs 2026 Q1+96 net · 387 entered · 291 exited
Shares reported, all filers749,539,811
Reported value, all filers$29.0B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustrySurgical & Medical Instruments & Apparatus (SIC 3841)
Revenue · FY2025$28.4B
Net income · FY2025$1.2B
Total assets · FY2025$38.5B
Shares outstanding810,000,000
Market cap (at latest close)$31.7B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.

Short interest

Shares short · Oct 15, 202640,816,957
Share of shares outstanding5.04%
Days to cover5.38

Shares short at recent settlements — Jul 31, 2026: 34.6M · Aug 14, 2026: 36.2M · Aug 31, 2026: 39.5M · Sep 15, 2026: 41.3M · Sep 30, 2026: 52.7M · Oct 15, 2026: 40.8M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.

Fails to deliver

Shares failed to deliver · Oct 14, 2026593
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 2026<0.1%

Fails to deliver at recent settlements — Jul 31, 2026: 4 · Aug 14, 2026: 1.5M · Aug 31, 2026: 8K · Sep 15, 2026: 0 · Sep 30, 2026: 17K · Oct 14, 2026: 593.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 6 sales by 1 insider ($996.4M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Oct 8, 2026GIC Private LtdSell7,816,987$35.15$274.8MSEC filing
Oct 6, 2026GIC Private LtdSell2,088,987$35.05$73.2MSEC filing
Oct 6, 2026GIC Private LtdSell7,183,013$35.05$251.8MSEC filing
Oct 5, 2026GIC Private LtdSell1,688,690$35.78$60.4MSEC filing
Oct 2, 2026GIC Private LtdSell2,570,999$35.35$90.9MSEC filing
Oct 2, 2026GIC Private LtdSell7,146,941$34.33$245.4MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Jun 16, 2026Douglas GolwasOfficer100,000$3.6MJun 16, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 11, 2026Hellman & Friedman Capital Partners X (Parallel), L.P.SC 13G/A61,054,6196.4%Jun 30, 2026SEC filing
Aug 7, 2026BX Mozart ML-2 Holdco L.P.SC 13G/A89,537,91310.2%Jun 30, 2026SEC filing
Aug 6, 2026FMR LLCSC 13G46,929,203.695.5%Jun 30, 2026SEC filing
May 15, 2026Carlyle Group Inc.SC 13G/A187,083,71320.6%Mar 31, 2026SEC filing
May 7, 2026Abu Dhabi Investment AuthoritySC 13G/A41,355,3404.9%Mar 31, 2026SEC filing
May 6, 2026Hellman & Friedman Capital Partners X (Parallel), L.P.SC 13G/A74,496,1727.9%Mar 31, 2026SEC filing
May 1, 2026BX Mozart ML-2 Holdco L.P.SC 13G/A109,250,23912.9%Mar 31, 2026SEC filing
Feb 13, 2026Carlyle Group Inc.SC 13G215,303,03624.4%Dec 31, 2025SEC filing
Feb 13, 2026Hellman & Friedman Capital Partners X (Parallel), L.P.SC 13G85,733,0229.2%Dec 31, 2025SEC filing
Feb 13, 2026Mozart Aggregator II LPSC 13G142,918,68017.6%Dec 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 138 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Trade (domestic/foreign) (95), Health Issues (78), Environment/Superfund (48).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Key figures

· Cash Flow (FCF) — Latest FCF: $1.3B · FCF yield: 5.0% · Positive FCF years: 3

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 3.41 · Operating cash flow: $1.7B · Net income: $1.2B

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q4, ranked #22 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together10.0%-3.2%+4.9%-8.0%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold MDLN — ranked by lift, the co-holding pattern described in Methodology: Oruka Therapeutics, Inc. (ORKA) · Interactive Brokers Group, Inc. (IBKR) · Natera, Inc. (NTRA) · CARVANA CO. (CVNA).

Recent 8-K filings

FiledItemsSource
Nov 18, 20261.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Nov 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 21, 20267.01 Regulation FD DisclosureSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Oruka Therapeutics, Inc. (ORKA) · Track Record: how the signals scored · Practice timing on MDLN

One email a week: the week’s new filings and research. Subscribe free

← MDGL  ·  MDLZ →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.